Clopidogrel bisulfate

Clopidogrel bisulfate (CAS 120202-66-6), also marketed under the salt forms clopidogrel hydrogen sulfate, is the active pharmaceutical ingredient form of clopidogrel used in the manufacture of antiplatelet medications.

It is the commercially dominant salt form selected for finished dose production due to its stability profile and processability in solid oral dosage manufacturing. Generic pharmaceutical manufacturers use it as the API in tablet formulations.

These formulations target cardiovascular indications, where precise polymorph control and purity are critical to regulatory submission. Contract development and manufacturing organizations source it as a starting point for 75 mg oral solid dose products.

This dosage represents the most common commercial strength globally. Formulators working on combination cardiovascular products also specify this salt form when developing fixed-dose combinations requiring compatibility with standard tablet excipients.

Clopidogrel bisulfate is supplied as a white to off-white crystalline powder. It is available in pharmaceutical-grade specifications aligned with USP and EP monograph requirements for global compliance.

Polymorph Form I is the standard commercially supplied crystalline form for this material. Packaging typically ranges from small analytical quantities through multi-kilogram lots to support clinical batch manufacturing.

These supply options are designed to facilitate both research and commercial-scale production. The material maintains high stability and purity standards necessary for the rigorous demands of the pharmaceutical industry.